about
Prevention of progression in monoclonal gammopathy of undetermined significanceMicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow MicroenvironmentSpotlight on ixazomib: potential in the treatment of multiple myelomaRole of osteocytes in multiple myeloma bone diseaseMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementRib fractures and death from deletion of osteoblast βcatenin in adult mice is rescued by corticosteroidsDual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaComputational modeling of interactions between multiple myeloma and the bone microenvironmentImmune complexes regulate bone metabolism through FcRγ signallingDasatinib as a bone-modifying agent: anabolic and anti-resorptive effectsIL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors.Osteoblastogenesis and tumor growth in myeloma.Advances in the understanding of myeloma bone disease and tumour growth.The effects of proteasome inhibitors on bone remodeling in multiple myeloma.Engineered nanomedicine for myeloma and bone microenvironment targeting.Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma.A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genesHeparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLMonoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.Diagnosis and management of neuropathies associated with plasma cell dyscrasias.A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivorsProton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsThe histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone lossunveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?A man with a fracture from minor traumaThe first Tianjin, China forum on tumor microenvironment.Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblastsBone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.Bone-immune cell crosstalk: bone diseases.Pathogenesis beyond the cancer clone(s) in multiple myeloma.Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.Evolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma.
P2860
Q24655581-118C139E-F418-4F9D-B6FD-ECDF6BDB71C2Q26765477-15B3D436-55B2-4DE5-B0D3-E332EA7AC6C3Q26774440-F2FC2FED-BFF7-40FD-B588-E45076059623Q26992195-460D187B-E9C2-425C-BC35-73018D48C9B1Q26998884-B439821F-AE58-43D7-BA77-13C9E54BF143Q27316361-3325B720-0854-43B3-AC2A-5AC9F4FDE64EQ28271286-5E574ADC-9F11-4719-9DD5-315801AB8DA2Q28477867-F965E2B5-8AE9-4316-B5B5-9926961BAE6FQ28512966-E157468D-9E75-4C9D-943B-9000916898F7Q28730433-5F437515-1DE0-4E57-A11F-5FF20E11AA2BQ33574203-D248FE5B-1F46-4936-BA4E-4ECC77B08912Q33719492-D134EB97-23D7-4EF3-816B-F96D8BDC4275Q33768466-8F60FF73-3028-42D8-973E-A3D87DB214CCQ33829022-F5DE35C7-5BB2-4B5A-B545-20E8A4449357Q33918020-7225FA27-846F-4EEF-80C0-2F1B499296D5Q33926003-3429C28A-E89D-48EE-A816-FDCE6308DC08Q33930081-4A0B3E39-FB2E-444C-9799-9DEDFED705D2Q34174284-073DD8F9-2F1C-4C6E-A6EF-122FC2182426Q34203659-316E1649-F844-4FEB-B58A-F1099299EA63Q34267974-BA1AA473-7F27-45BB-A009-E5A4EAEC8B47Q34316559-70295A8E-8B0E-4328-AF7E-04F7C846E832Q34423112-5924B986-476B-439E-8114-47D425884708Q34427554-FFAC1A03-1A8F-4D04-8358-8E451316AB58Q34555067-E51BF833-C6D3-4355-A045-DB6BDC848165Q34561380-07440AEF-B1BD-42FD-A04E-A13F48A11656Q34595084-6C9782C2-BC66-4F99-A653-711B66119638Q34617864-71AB3C93-D1F5-45F7-893C-BA89F502267DQ34686787-3C194330-CE61-479D-8B41-4E0D695CEC74Q34718186-91910DAE-33E0-41AF-80F5-AA3948E666D8Q34749546-177B9D03-FF3B-42A2-9FC7-304C8BBB66EEQ34786304-7AB1164C-165C-4DDC-BE43-9B96D945E767Q35067806-D38EF596-9661-467C-963D-9F653990E127Q35144762-1B16824D-8FFF-454C-BE5C-25E9535EDF4CQ35422468-0E676742-6756-4DDA-AE95-46D4804963C4Q35584866-917F1950-2334-4466-8025-CDC7FCB9F79FQ35592362-441ADD98-B8C7-4216-8CD1-E1D84FA36A5AQ35607266-7C1B31CE-704A-4687-988C-1E5041C42653Q35886257-3C5967FE-90F9-4BA2-AE02-4C47BB094590Q36054631-E38C9810-8EEF-4934-A681-223AFE2FFB0FQ36234799-C5FD2E06-EDA3-4792-A5FC-3787B152F635
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Pathogenesis of myeloma bone disease.
@en
Pathogenesis of myeloma bone disease.
@nl
type
label
Pathogenesis of myeloma bone disease.
@en
Pathogenesis of myeloma bone disease.
@nl
prefLabel
Pathogenesis of myeloma bone disease.
@en
Pathogenesis of myeloma bone disease.
@nl
P2860
P356
P1433
P1476
Pathogenesis of myeloma bone disease.
@en
P2093
G D Roodman
P2860
P2888
P304
P356
10.1038/LEU.2008.336
P577
2008-11-27T00:00:00Z
P5875
P6179
1018826299